<DOC>
	<DOCNO>NCT03079518</DOCNO>
	<brief_summary>Effects ferric carboxymaltose single HD ( 1000 mg ) infusion upon FGF23 patient isolate HFREF compare patient HFREF+CKD ( pt iron deficiency ) . This study aim identification optimal target population follow-up ( `` main '' ) study .</brief_summary>
	<brief_title>Intravenous Iron paTients With Heart failURe Reduced Ejection fracTion ( HFREF ) pLus Iron dEficiency</brief_title>
	<detailed_description>Iron deficiency highly prevalent patient HFREF intravenous high-dose ( HD ) iron application significantly improve clinically meaningful endpoint patient . The best evidence existent ferric carboxymaltose . Intravenous HD iron may influence phosphate metabolism via increase level intact FGF23 hence induce prolong hypophosphatemia . Such increase FGF23 may particularly occur depend type iron carrier . FGF23 significant risk factor mortality morbidity patient HFREF cardiac population risk may directly cause leave ventricular hypertrophy dysfunction . Hence , application i.v . HD iron may potentially beneficial effect cardiac function harmful effect via FGF23-induction hypophosphatemia time . However , FGF23 metabolism yet evaluate HFREF patient follow i.v . HD iron . FGF23 elevate patient chronic kidney disease . Patients HFREF + CKD = chronic cardio-renal syndrome particular risk regard elevate morbidity mortality . The effect intravenous HD iron upon phosphate FGF23 metabolism patient HFREF + CKD unknown effect set may different compare effect patient without pre-existing FGF23 stimulation .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Written inform consent . Age &gt; 18 yr Symptomatic HFREF ( LV ejection fraction &lt; 45 % ) optimal medical therapy ( OMT ) least 2 month Iron deficiency indicate ferritin &lt; 100 ng/mL ferritin 100299 ng/ml transferrin saturation ( TSAT ) &lt; 20 % Hb value &lt; 13mg/dl ( woman ) &lt; 14 mg/dl ( men ) Group A : Stable CKD least 2 month , define estimate glomerular filtration rate ( eGFR ) ( CKDEPI formula ) 1560 ml/min/1,73 m3 ( CKD III , IV , Vnon D ) Group B : patient stable eGFR &gt; 60 ml/min/1,73 m3 Known hypersensitivity ferric carboxymaltose constituent formulation , Plasma Phosphate &lt; 2.5 mg/dL screening , Renal replacement therapy/transplantation , Pregnancy lactation iron substitution therapy erythropoetin ( epo ) therapy within 6 week participation another clinical trial experimental drug expectation miss compliance alcohol drug abuse The subject mentally legally incapacitated patient relationship dependence work relationship sponsor , investigator representative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>iron deficiency</keyword>
	<keyword>HFREF</keyword>
	<keyword>FGF23</keyword>
	<keyword>ferric carboxymaltose</keyword>
</DOC>